Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

The purpose of this study is to elucidate the molecular mechanism by which novel adjuvants enhance the immunogenicity of Respiratory Syncytial Virus (RSV) vaccines by regulating antigen-specific B cell affinity maturation and T cell memory formation.

Participants needed: 60
Trial details
Age: 20+Biological sex: AllType: InterventionalSponsor: MAXVAX Biotechnology Limited Liability CompanyUpdated: Jun 1, 2026
Eligibility criteria

Participants must be 20 years of age or older as determined by the investigator... [+5]

Axillary body temperature ≥ 37.3 °C. [+27]

Read more
Status: Not yet recruiting

Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women

A Phase 1 study to evaluate safety, tolerability and immunogenicity a RSV vaccine in healthy women 18 to 49 years of age

Participants needed: 120
Trial details
Phase: Phase 1Age: 18-49Biological sex: FemaleType: InterventionalSponsor: MAXVAX Biotechnology Limited Liability CompanyUpdated: Mar 25, 2026Locations: 2
Eligibility criteria

Adult females 18-49 years old on the day of vaccination. [+4]

Recent RSV exposure/vaccination: History of RSV infection within 6 months or pri... [+23]

Read more
Status: Recruiting

Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell) vaccine .This study will also assess if the vaccine is safe and induces an immune response.

Participants needed: 25,000
Trial details
Phase: Phase 3Age: 60+Biological sex: AllType: InterventionalSponsor: MAXVAX Biotechnology Limited Liability CompanyUpdated: Dec 9, 2025Locations: 8
Eligibility criteria

A male or female can provide legal identification at the time of enrollment, and... [+3]

*Axillary temperature>37.3℃. [+25]

Read more
Status: Not yet recruiting

Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).

To evaluate the lot-to lot consistency of three batches of recombinant herpes zoster vaccine (CHO cell) produced on a commercial scale in subjects aged 40 years and older after receiving 2 doses on a 0, 2 month schedule.

Participants needed: 1,200
Trial details
Phase: Phase 3Age: 40+Biological sex: AllType: InterventionalSponsor: MAXVAX Biotechnology Limited Liability CompanyUpdated: Nov 20, 2024Locations: 1
Eligibility criteria

A male or female permanent resident aged 40 years and older at enrollment, with... [+3]

Axillary temperature > 37.0°C on the day of vaccination or acute illness; [+20]

Read more